BRIEF-Cosmo Pharmaceuticals: FDA Accepts New Drug Application Submission For Rifamycin SV MMX
1 Min Read
May 18 (Reuters) - Cosmo Pharmaceuticals NV:
* FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR RIFAMYCIN SV MMX AND SETS PDUFA DATE FOR NOVEMBER 16, 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)